Literature DB >> 15351555

Current and new strategies in immunotherapy for superficial bladder cancer.

Frank G E Perabo1, Stefan C Müller.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15351555     DOI： 10.1016/j.urology.2004.04.026

Source DB:  PubMed          Journal:  Urology        ISSN： 0090-4295            Impact factor:   2.649


× No keyword cloud information.
  8 in total

Review 1.  Keyhole limpet haemocyanin - a model antigen for human immunotoxicological studies.

Authors:  Ashwin Swaminathan; Robyn M Lucas; Keith Dear; Anthony J McMichael
Journal:  Br J Clin Pharmacol       Date:  2014-11       Impact factor: 4.335

Review 2.  Immune therapies in non-muscle invasive bladder cancer.

Authors:  Philip L Ho; Stephen B Williams; Ashish M Kamat
Journal:  Curr Treat Options Oncol       Date:  2015-02

3.  Relationship between HLA class I antigen processing machinery component expression and the clinicopathologic characteristics of bladder carcinomas.

Authors:  Helen P Cathro; Mark E Smolkin; Dan Theodorescu; Vickie Y Jo; Soldano Ferrone; Henry F Frierson
Journal:  Cancer Immunol Immunother       Date:  2009-09-16       Impact factor: 6.968

4.  Phase II study of intravesical therapy with AD32 in patients with papillary urothelial carcinoma or carcinoma in situ (CIS) refractory to prior therapy with bacillus Calmette-Guerin (E3897): a trial of the Eastern Cooperative Oncology Group.

Authors:  Jeffrey M Ignatoff; Yu-Hui Chen; Richard Evan Greenberg; Julio M Pow-Sang; Edward M Messing; George Wilding
Journal:  Urol Oncol       Date:  2008-07-17       Impact factor: 3.498

5.  Humoral anti-KLH responses in cancer patients treated with dendritic cell-based immunotherapy are dictated by different vaccination parameters.

Authors:  Erik H J G Aarntzen; I Jolanda M de Vries; Joop H Göertz; Marjo Beldhuis-Valkis; Huberdina M L M Brouwers; Mandy W M M van de Rakt; Renate G van der Molen; Cornelis J A Punt; Gosse J Adema; Paul J Tacken; Irma Joosten; Joannes F M Jacobs
Journal:  Cancer Immunol Immunother       Date:  2012-04-21       Impact factor: 6.968

6.  Monitoring of dynamic changes in Keyhole Limpet Hemocyanin (KLH)-specific B cells in KLH-vaccinated cancer patients.

Authors:  Florian Wimmers; Nienke de Haas; Anja Scholzen; Gerty Schreibelt; Elles Simonetti; Marc J Eleveld; Huberdina M L M Brouwers; Marjo Beldhuis-Valkis; Irma Joosten; Marien I de Jonge; Winald R Gerritsen; I Jolanda M de Vries; Dimitri A Diavatopoulos; Joannes F M Jacobs
Journal:  Sci Rep       Date:  2017-03-07       Impact factor: 4.379

7.  Reevaluating the concept of treating experimental tumors with a mixed bacterial vaccine: Coley's Toxin.

Authors:  C Maletzki; U Klier; W Obst; B Kreikemeyer; M Linnebacher
Journal:  Clin Dev Immunol       Date:  2012-11-11

Review 8.  Emerging intravesical therapies for management of nonmuscle invasive bladder cancer.

Authors:  Jeffrey J Tomaszewski; Marc C Smaldone
Journal:  Open Access J Urol       Date:  2010-05-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.